NO20055725L - Glutamatreseptorantagonister som neurobeskyttende midler - Google Patents

Glutamatreseptorantagonister som neurobeskyttende midler

Info

Publication number
NO20055725L
NO20055725L NO20055725A NO20055725A NO20055725L NO 20055725 L NO20055725 L NO 20055725L NO 20055725 A NO20055725 A NO 20055725A NO 20055725 A NO20055725 A NO 20055725A NO 20055725 L NO20055725 L NO 20055725L
Authority
NO
Norway
Prior art keywords
glutamate receptor
receptor antagonists
neuroprotective agents
neuroprotective
agents
Prior art date
Application number
NO20055725A
Other languages
English (en)
Other versions
NO20055725D0 (no
Inventor
Wolfgang Sohngen
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Publication of NO20055725D0 publication Critical patent/NO20055725D0/no
Publication of NO20055725L publication Critical patent/NO20055725L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

2005-12-02 174147-HJ Sammendrag Oppfinnelsen vedrører anvendelsen av en inhibitor av den t-PA-medierte aktiveringen av glutamatreseptoren, fortrinnsvis av NMDA-typen, som neurobeskyttende middel.
NO20055725A 2003-05-05 2005-12-02 Glutamatreseptorantagonister som neurobeskyttende midler NO20055725L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10337098 2003-05-05
DE10320336 2003-05-06
DE10352333 2003-11-06
PCT/EP2004/004776 WO2004098635A1 (de) 2003-05-05 2004-05-05 Glutamat-rezeptor-antagonisten als neuroprotektiva

Publications (2)

Publication Number Publication Date
NO20055725D0 NO20055725D0 (no) 2005-12-02
NO20055725L true NO20055725L (no) 2005-12-02

Family

ID=33436868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055725A NO20055725L (no) 2003-05-05 2005-12-02 Glutamatreseptorantagonister som neurobeskyttende midler

Country Status (12)

Country Link
US (1) US20080213244A1 (no)
EP (1) EP1622640A1 (no)
JP (1) JP2006525277A (no)
KR (1) KR20060015721A (no)
AU (1) AU2004237407A1 (no)
BR (1) BRPI0410055A (no)
CA (1) CA2524342A1 (no)
EA (1) EA200501753A1 (no)
HR (1) HRP20050898A2 (no)
MX (1) MXPA05011762A (no)
NO (1) NO20055725L (no)
WO (1) WO2004098635A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
DE602006009257D1 (de) * 2005-06-24 2009-10-29 Wilex Ag Verwendung von urokinase-inhibitoren zur behandlunklerose (als)
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
KR20060015721A (ko) 2006-02-20
BRPI0410055A (pt) 2006-04-25
CA2524342A1 (en) 2004-11-18
NO20055725D0 (no) 2005-12-02
JP2006525277A (ja) 2006-11-09
HRP20050898A2 (en) 2007-03-31
WO2004098635A1 (de) 2004-11-18
US20080213244A1 (en) 2008-09-04
EP1622640A1 (de) 2006-02-08
EA200501753A1 (ru) 2006-04-28
MXPA05011762A (es) 2006-03-30
AU2004237407A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
NO20034289D0 (no) N-(2-aryletylbenzylaminer som antagonister av 5-HT6- reseptoren
TNSN07196A1 (en) Potentiators of glutamate receptors
NO20074807L (no) Fast farmasoytisk doseringsformulering
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
NO20073244L (no) Konjugeringsprodukt
GEP20074078B (en) Fluoro substituted cyclo-alkanoindoles, compositions comprising them and their use
CY1110828T1 (el) Τροποποιημενοι πυριμιδινικοι ρυθμιστες του γλυκοκορτικοειδους υποδοχεα
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
NO20063393L (no) Farmasoytiske preparater
NO20081160L (no) Benzimidazoltiofen forbindelser
CY1107368T1 (el) Νεα παραγωγα 4-βενζυλιδενο-πιπεριδινης
SE0301653D0 (sv) Novel compounds
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
MEP15908A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
TW200519089A (en) Biaryl sulfonamides and methods for using same
TW200519100A (en) Biaryl sulfonamides and methods for using same
NO20025136D0 (no) Cykloheksylaminderivat som subtype selektive NMDA- reseptorantagonister
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
MY135916A (en) Use of certain affinity nmda antagonists as antidepressants
NO20055725L (no) Glutamatreseptorantagonister som neurobeskyttende midler
NO20065905L (no) Ny assosiasjon av en sinusknute If strominhibitor og en angiotensinkonvertaseinhibitor, og farmasoytiske sammensetninger inneholdende den

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application